Advertisement

Search Results

Advertisement



Your search for Linda T. Vahdat, MD,Linda T. Vahdat, MD matches 4 pages

Showing 1 - 4


breast cancer

Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment

Linda T. Vahdat, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses results of a phase II trial designed to test the concept that targeting the tumor microenvironment by depleting copper may prevent metastases, essentially disrupting the infrastructure that contributes to tumor spread.

New Cancer Care Collaboration Brings Memorial Sloan Kettering Cancer Care to Norwalk Hospital

NORWALK HOSPITAL and Memorial Sloan Kettering Cancer Center (MSK) announced a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital.  For...

breast cancer

Comparing Regimens Guides Therapeutic Decisions in Previously Treated Advanced Breast Cancer

Kaufman and colleagues recently reported findings of a phase III trial comparing eribulin ­(Halaven) vs capecitabine in patients with advanced breast cancer who had previously received anthracycline and taxane therapy,1 and a review of their study appears in this issue of The ASCO Post. Although...

breast cancer

Glembatumumab Vedotin Appears Active in Heavily Treated Advanced Glycoprotein NMB–Overexpressing Breast Cancer and Triple-Negative Disease

In the randomized phase II EMERGE study reported in the Journal of Clinical Oncology, Yardley et al found that the anti–glycoprotein NMB (gpNMB) antibody-drug conjugate glembatumumab vedotin may improve response rate over alternative chemotherapy in patients with advanced refractory breast...

Advertisement

Advertisement



Advertisement